Hibah Awwad, Ph.D.
Traumatic brain injury (TBI) is a leading cause of death and disability in young adults. To date, there are no FDA-approved drugs for TBI. The main focus of our research is to study the mechanisms of neurotoxic factors released after a brain injury, in order to identify potential targets for novel neuroprotective therapies. Scientific methods include neuropharmacology via molecular, biochemical, behavioral and imaging techniques.
Education & Experience
Ph.D. in Pharmacology
University of Houston, Houston, TX2005
B.Sc. in Pharmacy
Amman University, Amman, Jordan1998
Certificate in Preparing Future Faculty
University of Oklahoma Health Sciences Center, Oklahoma City, OK2010
Honors & Awards
Provost's Teaching Award for Early Career Faculty
University of Oklahoma Health Sciences Center, OKC, OK
Educator of the Year Award
University of Oklahoma College of Pharmacy
AACP WalMart Scholar
American Association of Colleges of Pharmacy (San Antonio general meeting)
Postdoctoral Travel Award
Society for Neuroscience (Washington, DC)2011
Postdoctoral Research Award (for scientific achievement - travel award)
Graduate College; University of Oklahoma Health Sciences Center, OKC, OK2010
Postdoctoral Scientific Research Award - Neuropharmacology Division
ASPET. Experimental Biology/Federation of American Societies. Experimental Biology (Anaheim, CA)2010
John B. Bruce Scholarship Award - Outstanding postdoctoral fellow in pharmaceutical Sciences
OU College of Pharmacy, Oklahoma City, OK2010
Publications & Presentations
- Baier M, Lerner M R, Awwad H O. Temporal changes in mast cell release following a mild traumatic brain injury in rats. Society for Neuroscience Annual Meeting Proceedings. 2017
- Oleru A V, Edwards A C, Awwad H O. Mild traumatic brain injury increases histamine-3-receptor expression. Journal of Neurotrauma. 2017; 34 : A-103
- Edwards A C, Johnston M P, Lerner M R, Abdelkader S H, Chen S, Awwad H O. Earlier recovery from vestibulomotor deficits compared to neurological deficits and increased pain sensitivity in rats with a mild traumatic brain injury. Society for Neuroscience Annual Meeting Proceedings. 2016
- Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2016
- Maltos K K, Stratton N C, Zhang Y, Awwad H O, Standifer K, M S D. Sources and suppression of autofluorescence in multi-channel immunofluorescent microscopy of formalin-fixed paraffin-embedded sections of brain and spinal cord tissue. J Histochem Cytochem. In Press
- Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock. 2017.
- Histamine release in Traumatic Brain Injury: neurotoxic or neuroprotective?. 2017.
- Unveiling neurotoxic mechanisms in a traumatic brain injury model. 2015.
- Molecular mechanisms of chronic pain and its modulation by posttraumatic stress disorder and Nociceptin/Orphanin FQ. 2011.
- Nociceptin/Orphanin FQ peptide (NOP) receptor antagonists for treatment of TBI-induced co-morbid chronic pain. 2014.